<DOC>
	<DOCNO>NCT00796666</DOCNO>
	<brief_summary>As monotherapy pulmonary arterial hypertension ( PAH ) begin fail additional therapy introduce . Although co-administration sitaxsentan sildenafil well tolerate control safety/efficacy database combination limit .</brief_summary>
	<brief_title>Study Looking Combination Therapy ( Sitaxsentan+Sildenafil ) Vs. Monotherapy ( Sitaxsentan Alone ) SR-PAAS -Sitaxsentan Efficacy And Safety Trial With A Randomized Prospective Assessment Of Adding Sildenafil</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Hypertension , Pulmonary</mesh_term>
	<mesh_term>Familial Primary Pulmonary Hypertension</mesh_term>
	<mesh_term>Endothelin Receptor Antagonists</mesh_term>
	<mesh_term>Sitaxsentan</mesh_term>
	<mesh_term>Sildenafil Citrate</mesh_term>
	<criteria>Previously enrol B1321001 ( NCT00795639 ) complete 12week study plan . Treated investigational drug , sitaxsentan sodium B1321001 ( NCT00795639 ) , device receive regulatory approval within 30 day prior Baseline/Day 1 study .</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>endothelin receptor antagonist ( ETRA )</keyword>
	<keyword>Sitaxsentan</keyword>
</DOC>